ArticleHIV medicine2026
UltRaSoUnd-guided evaLuAtion of metabolic health in a cohort of midlife women with HIV: The URSULA study.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe aimed to determine the prevalence of metabolic disorders, liver steatosis and metabolic dysfunction-associated steatotic liver disease (MASLD) in a cohort of middle-aged women with HIV (WoWH) and to explore associations between liver steatosis, visceral fat depots and carotid atherosclerosis. We also assessed the contribution of lifestyle, HIV- and antiretroviral therapy (ART)-related factors to liver steatosis and the accuracy of United States National Cholesterol Education Program/Adult Treatment Panel III (NCEP-ATP III) criteria in identifying at-risk patients.
methodsBetween 1 April and 31 July 2025, all ART-experienced WoWH aged ≥40 years received comprehensive metabolic and laboratory assessment, including abdominal and carotid Doppler ultrasound (US). Visceral fat depots were evaluated, and metabolic syndrome (MetS) was defined according to NCEP-ATP III criteria. Demographic, clinical and immunovirological data were collected. Logistic regression analyses identified factors associated with liver steatosis. Spearman correlations assessed associations between steatosis and fat distribution, and receiver operating characteristic (ROC) curves evaluated NCEP-ATP III accuracy in identifying liver steatosis.
resultsAmong 98 WoWH, 55 (56%) had at least grade I liver steatosis, 24 (25%) had MetS. Overall, MASLD was diagnosed in 41 participants (76%). Slight carotid intima-media thickness (cIMT) increases were observed, and 35 participants (36%) had carotid plaques. MetS was the main risk factor for steatosis (OR 14.14, 95% C.I. 3.23-84.40, p = 0.001), with no HIV- or ART-related associations. Progressive liver steatosis correlated with increasing retroperitoneal (rho = 0.393; p = 0.0001), subcutaneous (rho = 0.277; p = 0.005) and epicardial fat (rho = 0.312; p = 0.002) thickness. Conversely, epicardial fat thickness was not linked to cIMT. NCEP-ATP III criteria showed limited accuracy (AUC = 0.67) in identifying patients at risk for liver steatosis.
conclusionsIn the URSULA cohort, hepatic steatosis-largely driven by MetS-was highly prevalent and associated with abnormal visceral fat depots. US may offer a cost-effective tool for fast metabolic surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.